162 related articles for article (PubMed ID: 33054030)
1. [Rhabdomyosarcomas: structural distribution and analysis of an immunohistochemical profile].
Botiralieva GK; Sharlai AS; Roshchin VY; Sidorov IV; Konovalov DM
Arkh Patol; 2020; 82(5):33-41. PubMed ID: 33054030
[TBL] [Abstract][Full Text] [Related]
2. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
3. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
4. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience.
Morotti RA; Nicol KK; Parham DM; Teot LA; Moore J; Hayes J; Meyer W; Qualman SJ;
Am J Surg Pathol; 2006 Aug; 30(8):962-8. PubMed ID: 16861966
[TBL] [Abstract][Full Text] [Related]
5. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyosarcoma with epithelioid morphology: A challenging cytologic diagnosis in a pleural effusion.
Rodgers S; Datta L; Perry KD; Stone CH
Diagn Cytopathol; 2021 Sep; 49(9):E356-E359. PubMed ID: 34004052
[TBL] [Abstract][Full Text] [Related]
9. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
[TBL] [Abstract][Full Text] [Related]
10. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
11. Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study.
Zin A; Bertorelle R; Dall'Igna P; Manzitti C; Gambini C; Bisogno G; Rosolen A; Alaggio R
Am J Surg Pathol; 2014 Feb; 38(2):273-8. PubMed ID: 24418861
[TBL] [Abstract][Full Text] [Related]
12. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues.
Kumar S; Perlman E; Harris CA; Raffeld M; Tsokos M
Mod Pathol; 2000 Sep; 13(9):988-93. PubMed ID: 11007039
[TBL] [Abstract][Full Text] [Related]
13. Histopathological, immunohistochemical and molecular cytogenetic analysis of 21 spindle cell/sclerosing rhabdomyosarcomas.
Rekhi B; Singhvi T
APMIS; 2014 Nov; 122(11):1144-52. PubMed ID: 24730567
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid rhabdomyosarcoma: Report of the first case in the jaw.
de Aguiar MCF; de Noronha MS; Silveira RL; Araújo JAD; Werkema FS; Bell D; Caldeira PC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Nov; 130(5):e308-e315. PubMed ID: 32173396
[TBL] [Abstract][Full Text] [Related]
15. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
[TBL] [Abstract][Full Text] [Related]
16. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
[TBL] [Abstract][Full Text] [Related]
17. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
Rekhi B; Dodd L; Dharavath B; Dutt A
Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
[TBL] [Abstract][Full Text] [Related]
18. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
19. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Rekhi B; Upadhyay P; Ramteke MP; Dutt A
Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
[TBL] [Abstract][Full Text] [Related]
20. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
